Citi lowered the firm’s price target on Icon to $250 from $270 and keeps a Buy rating on the shares post the Q1 results. The analyst cites ongoing concerns among emerging biotech customers for the target drop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ICLR: